Physician profile
Mill Etienne
NPI 1720008907
$3,488.80
in general payments reported to CMS, 2019-2025
35 companies · $573 in 2025
The $573 reported for 2025 was more than what a typical Epilepsy provider received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $842 · 2020: $255 · 2021: $18.07 · 2022: $753 · 2023: $514 · 2024: $533 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619 · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.83 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $818.80 | 2022-2025 | |
| Sk Life Science, INC. | $695.72 | 2022-2024 | Xcopri |
| Emd Serono, INC. | $230.20 | 2019-2022 | |
| Ucb, INC. | $219.24 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $197.59 | 2019-2021 | |
| Lilly USA, LLC | $154.08 | 2019-2025 | Kisunla |
| Neuropace, INC. | $125.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $115.20 | 2022 | |
| Genzyme Corporation | $91.53 | 2019-2020 | |
| Allergan, INC. | $90.38 | 2019-2020 | |
| Greenwich Biosciences, INC. | $85.98 | 2019-2020 | |
| Assertio Therapeutics, INC. | $80.57 | 2019 | |
| Avanir Pharmaceuticals, INC. | $41.74 | 2020-2022 | |
| Eisai INC. | $40.07 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $39.92 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $39.08 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $38.26 | 2019 | |
| Csl Behring | $38.18 | 2019-2020 | |
| Pfizer INC. | $34.15 | 2019-2025 | |
| Boston Scientific Corporation | $32.27 | 2024 | General Dbs |
| Averitas Pharma INC. | $31.14 | 2024 | Qutenza |
| Novartis Pharmaceuticals Corporation | $30.30 | 2019 | |
| Vanda Pharmaceuticals INC. | $25.05 | 2020 | |
| Merz Pharmaceuticals, LLC | $21.20 | 2025 | Xeomin |
| Biogen, INC. | $20.66 | 2019 | |
| Kyowa Kirin, INC. | $20.59 | 2019 | |
| Grifols USA, LLC | $17.87 | 2019 | |
| Livanova USA, INC. | $17.70 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.22 | 2019 | |
| Tanabe Pharma America, INC. | $15.95 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.51 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.02 | 2019 | |
| Bausch Health US, LLC | $12.92 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.55 | 2019 | |
| Akcea Therapeutics, INC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mill Etienne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.